Provided By GlobeNewswire
Last update: Apr 22, 2025
CARMEL, Ind., April 22, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at and participate in the Citizens Life Sciences Conference on May 7 and the RBC 2025 Global Healthcare Conference on May 21.
Read more at globenewswire.comNASDAQ:MBX (10/24/2025, 2:58:35 PM)
16.635
+0.51 (+3.13%)
Find more stocks in the Stock Screener


